$HRGN
Harvard Apparatus Regenerative Technology, Inc.

2023 Q4 Form 10-Q Financial Statement

#000149315223040389 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q4
Revenue $63.00K $40.00K $0.00
YoY Change
Cost Of Revenue $11.00K $13.00K
YoY Change
Gross Profit $52.00K $27.00K
YoY Change
Gross Profit Margin 82.54% 67.5%
Selling, General & Admin $1.249M $1.312M $768.0K
YoY Change 62.63% 84.53% -85.65%
% of Gross Profit 2401.92% 4859.26%
Research & Development $631.0K $339.0K $725.0K
YoY Change -12.97% -8.13% 31.82%
% of Gross Profit 1213.46% 1255.56%
Depreciation & Amortization $6.000K $6.000K $12.00K
YoY Change -50.0% -53.85% -40.0%
% of Gross Profit 11.54% 22.22%
Operating Expenses $1.880M $1.664M $1.493M
YoY Change 25.92% 54.07% -74.7%
Operating Profit -$1.828M -$1.624M
YoY Change 50.37%
Interest Expense $64.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$62.00K $9.000K -$2.000K
YoY Change 3000.0% -62.5% -107.14%
Pretax Income -$1.826M -$1.615M -$1.495M
YoY Change 22.14% 52.94% -74.54%
Income Tax
% Of Pretax Income
Net Earnings -$1.826M -$1.615M -$1.580M
YoY Change 15.57% 52.94% -73.1%
Net Earnings / Revenue -2898.41% -4037.5%
Basic Earnings Per Share -$0.12
Diluted Earnings Per Share -$0.13 -$0.12 -$0.13
COMMON SHARES
Basic Shares Outstanding 13.95M shares 13.88M shares 11.64M
Diluted Shares Outstanding 13.88M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $432.0K $1.501M $1.241M
YoY Change -65.19% -49.48% -0.08%
Cash & Equivalents $432.0K $269.0K $1.241M
Short-Term Investments $1.232M
Other Short-Term Assets $297.0K $330.0K $51.00K
YoY Change 482.35% 55.66% 325.0%
Inventory $50.00K $56.00K
Prepaid Expenses
Receivables $4.000K $3.000K
Other Receivables $0.00 $0.00
Total Short-Term Assets $783.0K $1.890M $1.594M
YoY Change -50.88% -40.62% 0.44%
LONG-TERM ASSETS
Property, Plant & Equipment $73.00K $31.00K $49.00K
YoY Change 48.98% -60.26% -55.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.758M $1.758M $610.0K
YoY Change 188.2% 465.27%
Total Long-Term Assets $1.831M $1.892M $806.0K
YoY Change 127.17% 296.65% 188.89%
TOTAL ASSETS
Total Short-Term Assets $783.0K $1.890M $1.594M
Total Long-Term Assets $1.831M $1.892M $806.0K
Total Assets $2.614M $3.782M $2.400M
YoY Change 8.92% 3.33% 28.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $445.0K $424.0K $682.0K
YoY Change -34.75% -51.93% 0.89%
Accrued Expenses $522.0K $625.0K $669.0K
YoY Change -21.97% 40.77% -83.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $968.0K $1.055M $1.363M
YoY Change -28.98% -26.84% -71.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $11.00K $48.00K
YoY Change -100.0% 22.22% -18.64%
Total Long-Term Liabilities $0.00 $11.00K $48.00K
YoY Change -100.0% 22.22% -18.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $968.0K $1.055M $1.363M
Total Long-Term Liabilities $0.00 $11.00K $48.00K
Total Liabilities $968.0K $1.066M $1.411M
YoY Change -31.4% -26.53% -71.17%
SHAREHOLDERS EQUITY
Retained Earnings -$92.00M -$90.10M -$83.00M
YoY Change 10.84% 10.55% 7.88%
Common Stock $139.0K $139.0K $122.0K
YoY Change 13.93% 19.83% 12.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.646M $2.716M -$3.191M
YoY Change
Total Liabilities & Shareholders Equity $2.614M $3.782M $2.400M
YoY Change 8.92% 3.33% 28.62%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q4
OPERATING ACTIVITIES
Net Income -$1.826M -$1.615M -$1.580M
YoY Change 15.57% 52.94% -73.1%
Depreciation, Depletion And Amortization $6.000K $6.000K $12.00K
YoY Change -50.0% -53.85% -40.0%
Cash From Operating Activities -$1.218M -$3.162M -$1.733M
YoY Change -29.72% 83.94% 73.13%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$3.000K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $1.232M $1.291M
YoY Change
Cash From Investing Activities $1.232M $1.291M $3.000K
YoY Change 40966.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 149.0K 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.218M -3.162M -1.733M
Cash From Investing Activities 1.232M 1.291M 3.000K
Cash From Financing Activities 149.0K 0.000 0.000
Net Change In Cash 163.0K -1.871M -1.730M
YoY Change -109.42% 8.84% 129.75%
FREE CASH FLOW
Cash From Operating Activities -$1.218M -$3.162M -$1.733M
Capital Expenditures $0.00 $0.00 -$3.000K
Free Cash Flow -$1.218M -$3.162M -$1.730M
YoY Change -29.6% 83.94% 72.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001563665
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
usd
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
usd
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2022Q3 HRGN Cost Of Sales
CostOfSales
usd
HRGN Cost Of Sales
CostOfSales
usd
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
usd
CY2023Q3 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
usd
HRGN Stock Issued During Period Value New Issues One
StockIssuedDuringPeriodValueNewIssuesOne
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
usd
HRGN Increase Decrease In Prepaid Research And Development
IncreaseDecreaseInPrepaidResearchAndDevelopment
usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
usd
HRGN Settlement Of Contingency Matter
SettlementOfContingencyMatter
usd
HRGN Settlement Amount Due To Parent Included In Accrued And Other Current Liabilities
SettlementAmountDueToParentIncludedInAccruedAndOtherCurrentLiabilities
usd
us-gaap Stock Issued1
StockIssued1
usd
HRGN Purchases Of Property And Equipment In Accounts Payable Or Accrued Expenses
PurchasesOfPropertyAndEquipmentInAccountsPayableOrAccruedExpenses
usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
usd
CY2023Q3 us-gaap Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration
PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
http://fasb.org/us-gaap/2023#UsefulLifeTermOfLeaseMember
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
usd
CY2022Q4 HRGN Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
usd
CY2023Q3 HRGN Accrued Legal Expenses Current
AccruedLegalExpensesCurrent
usd
CY2023Q3 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35853
dei Entity Registrant Name
EntityRegistrantName
Harvard Apparatus Regenerative Technology, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5210462
dei Entity Address Address Line1
EntityAddressAddressLine1
84 October Hill Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 11
dei Entity Address City Or Town
EntityAddressCityOrTown
Holliston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01746
dei City Area Code
CityAreaCode
(774)
dei Local Phone Number
LocalPhoneNumber
233-7300
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13947324 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
269000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1241000 usd
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
1232000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
56000 usd
CY2023Q3 HRGN Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
210000 usd
CY2022Q4 HRGN Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
274000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
120000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
79000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
1890000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1594000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
103000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
147000 usd
CY2023Q3 HRGN Deferred Financing Cost Non Current
DeferredFinancingCostNonCurrent
544000 usd
CY2022Q4 HRGN Deferred Financing Cost Non Current
DeferredFinancingCostNonCurrent
610000 usd
CY2023Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
1214000 usd
CY2023Q3 us-gaap Assets
Assets
3782000 usd
CY2022Q4 us-gaap Assets
Assets
2400000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
424000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
682000 usd
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
539000 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
582000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
92000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
99000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1055000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1363000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
48000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
1066000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1411000 usd
CY2023Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
5000 shares
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
5000 shares
CY2023Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
4180 shares
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
4180 shares
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
4180000 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13882060 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13882060 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12174467 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12174467 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
139000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
122000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
92707000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
79698000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90130000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-83011000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2716000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3191000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3782000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2400000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
40000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
40000 usd
CY2023Q3 HRGN Cost Of Sales
CostOfSales
13000 usd
HRGN Cost Of Sales
CostOfSales
13000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
339000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
369000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2414000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
998000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
143000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
198000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1169000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
711000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4577000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3662000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1664000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
1080000 usd
us-gaap Operating Expenses
OperatingExpenses
7202000 usd
us-gaap Operating Expenses
OperatingExpenses
4660000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1624000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1080000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7162000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4660000 usd
CY2023Q3 HRGN Sublease Expense Income
SubleaseExpenseIncome
-5000 usd
CY2022Q3 HRGN Sublease Expense Income
SubleaseExpenseIncome
26000 usd
HRGN Sublease Expense Income
SubleaseExpenseIncome
-5000 usd
HRGN Sublease Expense Income
SubleaseExpenseIncome
87000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
48000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
24000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
43000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
82000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1615000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1056000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7119000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4578000 usd
CY2022Q3 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
77000 usd
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
77000 usd
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
95000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1615000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1133000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7196000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4673000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13882060 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13882060 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11615642 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11615642 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13297391 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13297391 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11205477 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11205477 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3796000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
535000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1615000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2716000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-997000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
-77000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
244000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1056000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1886000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3191000 usd
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
-77000 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
4257000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5992000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2854000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7119000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2716000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-3029000 usd
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
-95000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5060000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
756000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4578000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1886000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7119000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4578000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2854000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
756000 usd
us-gaap Depreciation
Depreciation
29000 usd
us-gaap Depreciation
Depreciation
40000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
44000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
81000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
56000 usd
HRGN Increase Decrease In Prepaid Research And Development
IncreaseDecreaseInPrepaidResearchAndDevelopment
-64000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
41000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-83000 usd
HRGN Increase Decrease In Deferred Financing Costs
IncreaseDecreaseInDeferredFinancingCosts
-66000 usd
HRGN Increase Decrease In Deferred Financing Costs
IncreaseDecreaseInDeferredFinancingCosts
311000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1214000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-258000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
206000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-44000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-81000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-43000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
433000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5721000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3373000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
2523000 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
1291000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1243000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5992000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5060000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5992000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5060000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-972000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1679000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1241000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1292000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
269000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2971000 usd
HRGN Settlement Of Contingency Matter
SettlementOfContingencyMatter
-3250000 usd
HRGN Settlement Amount Due To Parent Included In Accrued And Other Current Liabilities
SettlementAmountDueToParentIncludedInAccruedAndOtherCurrentLiabilities
-750000 usd
us-gaap Stock Issued1
StockIssued1
4000000 usd
HRGN Purchases Of Property And Equipment In Accounts Payable Or Accrued Expenses
PurchasesOfPropertyAndEquipmentInAccountsPayableOrAccruedExpenses
3000 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
77000 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
95000 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
4257000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90100000 usd
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
1500000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_843_eus-gaap--UseOfEstimates_zWxNbvexEEm2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zquUlhPp1Dui">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The process of preparing condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, share-based compensation, valuation of warrant liability, accrued expenses and the valuation allowance for deferred income taxes. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6909000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2109399 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zbg0jz52VNSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z9hq6F161IDk">Cash Concentrations </span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains its cash balances with a financial institution in federally insured accounts and may periodically have cash balances in excess of insurance limits. The Company maintains its accounts with financial institutions with a high credit rating. The Company has not experienced any losses to date and believes that it is not exposed to any significant credit risk on cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2516924 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.95
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
1200000 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
18000 usd
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
0 usd
us-gaap Interest Income Other
InterestIncomeOther
59000 usd
us-gaap Interest Income Other
InterestIncomeOther
0 usd
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
300000 usd
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
1200000 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
1200000 usd
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
1232000 usd
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M4D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6917000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2120913 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
593333 shares
CY2023Q3 HRGN Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
39000 usd
CY2023Q3 HRGN Accrued Advisory Costs Current
AccruedAdvisoryCostsCurrent
300000 usd
CY2022Q4 HRGN Accrued Advisory Costs Current
AccruedAdvisoryCostsCurrent
300000 usd
CY2022Q4 HRGN Accrued Legal Expenses Current
AccruedLegalExpensesCurrent
135000 usd
CY2023Q3 HRGN Accrued Audit Services Current
AccruedAuditServicesCurrent
84000 usd
CY2022Q4 HRGN Accrued Audit Services Current
AccruedAuditServicesCurrent
80000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
110000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
55000 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12000 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
539000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
582000 usd
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.12
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4044504 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.61
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M4D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.70
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M21D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4605000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3945086 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.65
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y11M4D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
6667000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0382 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0271 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2538 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.2353 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
535000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
244000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2854000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
756000 usd
CY2022Q4 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
5900000 usd
CY2023Q3 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
5900000 usd
us-gaap Sublease Income
SubleaseIncome
61000 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0935 pure
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
103000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
147000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
92000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
99000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
48000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
103000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
147000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
33000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
30000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
89000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
91000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
33000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
89000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
30000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
91000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y7M28D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y11M8D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1277 pure
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
33000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
69000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
107000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
103000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1615000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1056000 usd
us-gaap Net Income Loss
NetIncomeLoss
-7119000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4578000 usd
CY2022Q3 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
77000 usd
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
77000 usd
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
95000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1615000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1133000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7196000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4673000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13882060 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13882060 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11615642 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11615642 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13297391 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13297391 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11205477 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11205477 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5158126 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5050240 shares
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001493152-23-040389-index-headers.html Edgar Link pending
0001493152-23-040389-index.html Edgar Link pending
0001493152-23-040389.txt Edgar Link pending
0001493152-23-040389-xbrl.zip Edgar Link pending
ex10-2.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
hrgn-20230930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
hrgn-20230930_cal.xml Edgar Link unprocessable
hrgn-20230930_def.xml Edgar Link unprocessable
hrgn-20230930_lab.xml Edgar Link unprocessable
hrgn-20230930_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable